January Emerging Medical Technologies Report

101 Pages | 47 Exhibits |

Order individually or subscribe to Medtech Pro and get a complete intel platform.


This report includes details on 47 emerging medical technology companies that have been identified by LSI's in-house research team in January 2012.

All companies include technology, market(s), key executive, and contact information.

Two- to three-page executive summaries are provided on most of the companies. Executive summaries typically include:

• Company Contact Information
• Company Overview (structure, size, year founded, etc.)
• Competitive Landscape
• Technological Advantage
• Stage of Development
• Target Markets
• Financial Summary and Sales Forecasts
• Financing & Partnering Needs
• IP Position & Status
• Management Team
• Exit Strategy
• More

Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies

This report is included in LSI's Emerging Medical Technologies® Database.

Table of Contents


• A battery-powered device which lifts and acquires a healthcare patient weighing up to 500 lbs. - without any caregiver's touching, logrolling, or lifting - and transports them to the next destination, then gently discharges them onto the desired horizontal surface
• A bionic retina designed to restore sight to millions blinded by retinal degenerative diseases
• A molecular diagnostics test that examines somatic alterations in cancer-related genes by applying massively parallel sequencing to routine clinical specimens, enabling targeted therapy
• A nanotechnology-enabled portfolio of therapeutic products for use in medical applications
• A next-generation eye drop medication that uses Rho-kinase inhibitors to treat glaucoma
• A novel annuloplasty ring for heart valve repair. The Intra-annular Ring represents a unique solution for children allowing the valve to grow following implantation.
• A range of injectable gels made from hyaluronic acid for applications in Aesthetic Dermatology, Ophthalmology, and Orthopaedics
• An aerosolized long-acting muscarinic antagonist that treats chronic obstructive pulmonary disease (COPD)
• An inhaler with variable dosage of Asthma medicine, based on a built-in exhaling measurement of the airway obstruction level
• An oral delivery platform for medications, food supplements, and other soluble substances that is easy-to-use, friendly, inexpensive, and requires no third-party assistance
• Electronic stimulation technologies that maintain muscle strength during recovery in the intensive care unit or other periods of inactivity
• Endoear(R) is the world's first implantable hearing device of its kind, created for the treatment of mild to moderate hearing loss
• Implantable drug delivery device using nanochannel-based chip to control/modulate release
• Implantable vagus nerve stimulation system for the treatment of tinnitus and post-stroke motor rehabilitation
• Innovative central nervous system therapies; Allon is proceeding in a fully enrolled pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP)
• Innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders such as migraine, Parkinson's disease, schizophrenia, and bipolar disorder
• Innovative new topical therapies for dermatology applications, including photodynamic therapy for sebaceous gland disorders and small molecule therapeutics that treat acne, inflammatory skin diseases, and sebaceous gland hyperactivity
• Long-acting, intravenous lipoglycopeptide used to treat acute bacterial skin and skin structure infections
• Micro-format, CMOS-based, imaging technology for minimally-invasive, disposable endoscopic medical procedures
• Nanofibers designed for use in tissue engineering, drug delivery, and wound care
• New gene-based medicines to treat "dominant" genetic diseases, particularly for the eye
• Non-invasive, rapid, quantitative measurement of metabolic health of the retina using a novel spectroscopic biomarker
• Novel drugs that treat cancer by targeting cellular protein homeostasis pathways
• Novel metal abstraction peptide (MAP) platform technology that delivers platinum to cancer cells by incorporating it into cancer-targeting proteins, thereby improving treatment while limiting side effects and damage to healthy cells
• Novel, minimally invasive surgical devices for the treatment of sinusitis
• Oncology drugs that utilize novel mechanisms of action
• Products for minimally invasive bypass surgery
• Proprietary technology for decellularizing biological organs/tissues to create an extra-cellular matrix retaining its original architecture, mechanical properties, and vascular network - suitable for scaffold transplantation or growing new functional organs/tissues by recellularization
• Pro-Vas is a novel less-invasive alternative to vasectomy for men seeking permanent contraception
• Ready-to-market medical device for assessing - via the eye - exposure to neurotoxins, cyanide, and low level radiation. Future products include assessment of mild TBI and other health conditions, including diabetic diseases of the eye.
• Real-time, non-contact, high resolution tissue temperature monitoring & mapping products that improve the safety and efficacy of ablation therapy by avoiding injury to surrounding tissue
• Requiring only one drop of blood, the proprietary LBIdx(TM) Plasma Thermogram(TM) tests will significantly improve the clinical diagnosis and monitoring of autoimmune disease and cancer, vastly improving patient outcomes
• Sutureless, adjustable mitral annuloplasty toolset for surgical and robotic procedures
• Technology that has demonstrated its usefulness in tracking all facets of in vivo oxygen metabolism using normally installed MRI scanners
• Technology that provides an immediate cardiovascular risk prediction for major chronic diseases, such as diabetes. The method is convenient, easy-to-use, and validated. It measures tissue accumulation of Advanced Glycation End products (AGEs) by means of fluorescence techniques. AGEs play a key role in the pathogenesis of many age-related diseases, such as diabetes and cardiovascular disease.
• The fentanyl iontophoretic transdermal system (IONSYS), an investigational, pre-programmed drug delivery system comprising a compact, needle-free, self-contained system that provides patient-controlled analgesia for adult inpatients requiring post-operative opioid therapy
• The first home-based telemonitoring system for patients with age-related macular degeneration, the leading cause of blindness in people over age 50 in the western world
• The patented EXMI technology uses pulsed magnetic fields that penetrate up to 7,5 cm into the body, stimulating nerves (neuromodulation), contracting muscles (rehabilitation), treating pain/depression, and increasing blood flow
• The Renaissance(TM) Surgical Guidance System is transforming spine surgery from freehand procedures to highly-accurate, state-of-the-art operations that raise the standard of care with better clinical outcomes
• The RGS Vertex360(TM), which competes with the Gamma knife in the non-invasive treatment of brain tumors, is a highly precise cobalt 60 radiation system that utilizes the OsiriX(TM) based Explorer 4D(TM) treatment planning system, also developed by the company
• The Rx Timer Cap is a patented "smart cap" with a built-in LCD timer that fits common prescription vials and lets patients know exactly how long it has been since they last took their medication
• Third-generation transcatheter aortic valve prosthesis with increased safety, greater ease-of-use, and longer durability
• Two novel technologies that boost immune responses, including a synthetic toll-like receptor agonist for use as an adjuvant to vaccines , and a viral vector that targets immature dendritic cells
• Ultrasonic devices for non-invasive fat removal from the chin, arm, and eye-bags and for skin tightening
• Vaccine platform technology for cancer and infectious diseases based on Listeria monocytogenes that has been engineered to be safe for use in humans and express and specific disease antigens
• Vascular closure device that seals the femoral artery following cardiac catherization
• Ventritek 105 is a novel medical device that provides full treatment for Stroke/SAH/ICH patients by replacing the current long and risky procedure

Companies We Work With